Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

被引：2
|
作者：
Labriola, Matthew
Zhu, Jason
Gupta, Rajan
McCall, Shannon
Jackson, Jennifer
White, James R.
Weingartner, Elizabeth
Kong, Eric
Simone, Peter
Papp, Eniko
Gerding, Kelly
Simmons, John
George, Daniel J.
Zhang, Tian
机构：
[1] Duke Med Ctr, Durham, NC USA
[2] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Personal Genome Diagnost Inc, Baltimore, MD USA
[5] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[6] Duke Univ, Canc Inst, Durham, NC USA
[7] Duke Univ, Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e16079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16079
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).
    Nuzzo, Pier Vitale
    Curran, Catherine
    Adib, Elio
    Freeman, Dory
    Nassar, Amin
    Abou Alaiwi, Sarah
    Bakouny, Ziad
    McGregor, Bradley Alexander
    Choueiri, Toni K.
    Jain, Rakesh K.
    McKay, Rana R.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
    Castellanos, Emily
    Snider, Jeremy
    Ali, Siraj Mahamed
    Backenroth, Daniel
    Albacker, Lee A.
    Murugesan, Karthikeyan
    Li, Gerald
    Frampton, Garrett M.
    Alexander, Brian Michael
    Carson, Kenneth Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [24] Absolute eosinophil count as predictive biomarker of irAEs in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs).
    Giorgione, Roberta
    Pillozzi, Serena
    Mela, Marinella Micol
    Giommoni, Elisa
    Paderi, Agnese
    Doni, Laura
    Pellegrini, Elisa
    Di Costanzo, Alessandro
    Antonuzzo, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [25] Association of serum iron and response to immune checkpoint inhibitors (ICIs) in metastatic clear cell renal cell carcinoma (mccRCC)
    Rathi, Nityam
    Stenehjem, David D.
    Agarwal, Neeraj
    Hahn, Andrew W.
    Sirohi, Deepika
    Sharma, Prayushi
    Koh, Mei Yee
    Maughan, Benjamin Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC).
    Derosa, Lisa
    Le Teuff, Gwenael
    Khordahi, Manal
    Chanez, Brice
    Zalcman, Emanuelle
    Gravis, Gwenaelle
    Negrier, Sylvie
    Radulescu, Camelia
    Albiges, Laurence
    Merabet, Zahira
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
    Zhu, Jason
    Labriola, Matthew
    Cheris, Sachica
    Liu, Xin
    Perkinson, Kathryn
    Su, Zuowei
    McCall, Shannon
    Huang, Jiaoti
    Gupta, Rajan
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
    Labriola, Matthew
    Zhu, Jason
    Cheris, Sachica
    Liu, Xin
    Perkinson, Kathryn
    Su, Zuowei
    McCall, Shannon
    Huang, Jiaoti
    Gupta, Rajan T.
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression
    Li, Yunfeng
    Hu, Maitao
    Li, Lei
    Liu, Sheng
    He, Tingting
    Cheng, Chunyan
    Xu, Mian
    Yin, Xinmin
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (01)
  • [30] PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    CANCERS, 2021, 13 (03) : 1 - 11
12345